Acquisition
Video: Valeant buys rights to Visudyne Add to ...
Valeant Pharmaceuticals has purchased the rights to Visudyne, an eye drug, from Vancouver-based QLT Inc.
Watch More Video:
-
Do we still need real estate agents?
Macy's rings up $6.39-billion sales
Retail sales unexpectedly rise
Briton jailed for bomb detector scam
-
Stressed consumers are paying more - but not getting more
McDonald's: Slow times for fast food
Long winter cools H&M sales
Daily Digit: U.S. retail sales slip again
-
Lukewarm retail sales blamed on weather chill
Car prices on the rise as auto industry picks up speed
B.C. makes history by eliminating HST
How long can S&P home-building stocks outpace index average?
-
After dead pig scandal, worries about safety of China's pork
Easier credit bringing car buyers back
How to attract and then hold onto good salespeople
How to sell in a brave new digital world
-
BNN's upgrades and downgrades
Tornado insurance losses to cost up to $5-billion
Daily Digit: 43.8 gallons of soft drinks
A Slice of Apple History Up for Grabs
| Security | Price | Change | |
|---|---|---|---|
| QLT-T QLT Inc. | 8.09 |
-0.04 -0.492% |
Add to watchlist |
| VRX-T Valeant Pharmaceuticals Intl. | 87.02 |
10.18 13.248% |
Add to watchlist |
